Navigation Links
Rigel Announces Third Quarter 2009 Financial Results
Date:11/3/2009

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009.

For the third quarter of 2009, Rigel reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Weighted average shares outstanding for the third quarters of 2009 and 2008 were 38.1 million and 36.6 million, respectively.

Rigel reported total operating expenses of $26.7 million in the third quarter of 2009, compared to $38.7 million in the third quarter of 2008. The decrease in operating expenses was primarily due to the completion of two Phase 2b clinical trials (TASKi2 and TASKi3) in July, a decrease in stock-based compensation expense, and cost savings resulting from our restructuring implemented in the first quarter of 2009. Stock-based compensation expenses decreased from $6.0 million in the third quarter of 2008 to $3.5 million in the third quarter of 2009, primarily due to a higher valuation of options granted in the first quarter of 2008 and full expense recognition of the majority of those options by the end of 2008.

For the nine months ended September 30, 2009, Rigel reported a net loss of $86.5 million, or $2.32 per share, compared to a net loss of $99.0 million in the first nine months of 2008, or $2.76 per share.

As of September 30, 2009, Rigel had cash, cash equivalents and available for sale securities of $156.1 million, compared to $134.5 million as of December 31, 2008. In September 2009, Rigel completed a public offering in which it sold 14,950,000 shares of common stock at a public offering price of $7.25 per share. The aggregate net proceeds of the offering were approximately $101.5 million after ded
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces Presentations at Two Investor Conferences
2. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
3. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
4. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
9. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
10. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Dec. 17 Pharmaceutical Institute today announced ... Inc., a company specializing in life science courseware. ... help expand Pharmaceutical Institute,s already extensive library of ... a leading provider of specialized training solutions for ... of Campbell Alliance. Financial terms of the ...
(Date:12/17/2009)... 17 BASF today announced ... the use of Aseptrol® S10 - Tab in ... such as, schools, hospitals, government buildings, retail and ... Tab is based on Chlorine dioxide (CIO2) release ... a broad spectrum disinfectant as stated in the ...
(Date:12/16/2009)... Tenn. , Dec. 16 MedSolutions ... cost management services, today commended two new studies ... CT scans and other diagnostic imaging tests. ... to proper diagnosis and treatment," said Gregg Allen, ... new studies offer more compelling evidence that stricter ...
Breaking Medicine Technology:Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 2BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 3MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3Video 3A Sodexo Takes on Childhood Obesity in School Cafeterias 51760 1Video 3A Sodexo Takes on Childhood Obesity in School Cafeterias 51760 2Video 3A Sodexo Takes on Childhood Obesity in School Cafeterias 51760 3Video 3A Sodexo Takes on Childhood Obesity in School Cafeterias 51760 4CSC Signs 24115 Million IT Services Renewal Agreement With Henry Ford Health System 51756 1CSC Signs 24115 Million IT Services Renewal Agreement With Henry Ford Health System 51756 2Morphotek 28R 29 Inc and Cancer Innovations Inc Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 13039 1Morphotek 28R 29 Inc and Cancer Innovations Inc Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 13039 2Morphotek 28R 29 Inc and Cancer Innovations Inc Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 13039 3
... SpectraScience, Inc. (OTC Bulletin Board: SCIE) , a ... Moines Register published an article reporting that its LUMA cervical imaging ... University of Iowa . Since Last July, researchers at the ... have used the LUMA Cervical Imaging System in more than 80 ...
... Arrayit Corporation (OTC Bulletin Board: ARYC), a leading manufacturer ... cure, announced today that it is developing a microarray-based ... The Arrayit test will allow researchers and clinicians to ... and livestock and to distinguish the threatening mutated strain ...
Other Medicine Technology:Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 2Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 3Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip 2Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip 3
(Date:12/17/2009)... CareFusion Corporation (NYSE: CFN ) announced today ... offer by TRC Capital Corporation (TRC) to purchase up ... approximately 1.8 percent of the shares of common stock ... 4.62 percent below the share closing price of CareFusion ... trading day prior to the offer. CareFusion also noted ...
(Date:12/17/2009)... John Howell, CEO of Arrayit ... Corporation (OTC Bulletin Board: ARYC), today formally ... of its microarray-based OvaDx(TM) Pre-Symptomatic ... advancing through late-stage development - the rights ... the Company by Arrayit Corporation. ,, Howell ...
(Date:12/17/2009)... LONDON, December 17 Researchers from the ... Loughborough University in the UK are today,encouraging ... in the,New Year following concerning research* that shows ... together as a family (68%), with the,Portuguese being ... likely to,walk together. , ...
(Date:12/17/2009)... American adults who serve as a family caregiver , ... ... on Mental Illness (NAMI) praises a new report, Caregiving in ... nearly one-in-three American adults who serve as a family caregiver. , ... at random and offers a national profile of people caring for ...
(Date:12/17/2009)... the past three years and what has driven these changes ... ... the human capital research firm, will host a webinar titled “The ... hour-long webinar will be broadcast on Wednesday, January 27, 2010 at ... SVP, Consulting Services and Trevor Byrd, Ph.D., a Morehead Consultant, as ...
Breaking Medicine News(10 mins):Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2
... Patients who are mentally ill, and in the care ... challenge decisions concerning their care and treatment, Health// Minister ... of Mental Health Review Board members, at Weskoppies psychiatric ... to change the practice from the past that mental ...
... proportionate to his socioeconomic status. A recent study by ... smoking as the cause for death risk among men in ... class. ,The study, which appears online in the ... men aged 35 to 69 years in the U.K., Canada, ...
... UNICEF has urged that the orphans and vulnerable children (OVC) ... , ,In their new report, 'A Call to Action: ... vigour to tackle the distress of children and also to ... on AIDS, child mortality and maternal health, for the year ...
... women with early breast cancer who have been receiving ... more modern therapy with the drug//, Arimidex under a ... ,The company AstraZeneca has stated that Arimidex, an ... have already received a partial course of tamoxifen.The license ...
... investigation has revealed that some homeopathic clinics advice people ... of the world.// ,People planning on taking ... avoid homeopathic remedies that are claiming to prevent malaria, ... ,It was reported that every year almost around ...
... Australia have performed the first incompatible blood group kidney ... hospital have performed a kidney transplant despite the donor ... that Davorin Gelemanovic, 24, who is of the blood ... father, who has type A blood. Mr Gelemanovic says ...
Other Medicine News:Health News:Study finds Smoking Mortality Higher Among Lower Economy Class 2Health News:Travellers Cautioned Over The Alternate Remedies For Malaria 2
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Microsurgical curved forceps made of titanium has curved shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Angled tying forceps made of titanium has angled shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 102 mm....
Medicine Products: